Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GEMINI THERAPEUTICS, INC.

(GMTX)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
1.640 USD   +7.89%
09/19Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from S&P Global BMI Index
CI
08/12Gemini Therapeutics Investor Alert By The Former Attorney General Of Louisiana : Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTX
BU
08/11GEMINI THERAPEUTICS, INC. /DE Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Disc Medicine, Inc. entered into an agreement to acquire Gemini Therapeutics, Inc. in a reverse merger transaction.

08/10/2022 EDT

Disc Medicine, Inc. entered into an agreement to acquire Gemini Therapeutics, Inc. (NasdaqGM:GMTX) in a reverse merger transaction on August 9, 2022. Under the terms of the all stock transaction, based on the exchange ratio, pre-merger Gemini shareholders will own approximately 28% of the combined company and pre-merger Disc stockholders will own approximately 72% of the combined company. The percentage of the combined company that Gemini's shareholders will own as of the close of the transaction is subject to adjustment based on the amount of Gemini's net cash at the closing date. In support of the merger, Disc has secured commitments from a syndicate of healthcare investors led by Access Biotechnology and including OrbiMed, Atlas Venture, 5AM Ventures, Novo Holdings A/S, Arix Bioscience, Rock Springs Capital, and Janus Henderson Investors, for a $53.5 million financing that is expected to close concurrent with the completion of the merger. Upon closing of the transaction, the combined company is expected to operate under the name Disc Medicine, Inc. and trade on the Nasdaq Global Market under the ticker symbol IRON. Disc will pay a termination fee of $7.8 million to Gemini, in case Disc terminates the transaction. Gemini will pay a termination fee of $3 million to Disc, in case Gemini terminates the transaction.

Following the merger, the combined company will be led by John Quisel, the current Chief Executive Officer and President of Disc Medicine, and other members of the Disc management team. The Board of Directors of the combined company will be composed of nine members, including eight Disc board members and one from Gemini. Georges Gemayal, Chair of the Board and Interim Chief Executive Officer of Gemini, will be continuing as a Director of the combined company. Gemini Therapeutics, Inc. will be renamed “Disc Medicine, Inc.” and the corporate headquarters will be located in Watertown, MA. The transaction has been unanimously approved by the Board of Directors of both companies. The transaction is subject to approvals by the stockholders of both companies; Nasdaq's approval of the listing of the shares of Gemini common stock to be issued in connection with the merger; effectiveness of the Registration Statement; and other customary closing conditions. Certain stockholders of Disc holding approximately 90% of the outstanding shares of Disc and certain stockholders of Gemini holding approximately 36% of the outstanding shares of Gemini have entered into support agreements to vote in favor of the transaction. The transaction is expected to close in the fourth quarter of 2022.

Stuart M. Falber and Christopher D. Barnstable-Brown of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor; and SVB Securities acted as financial advisor to Gemini Therapeutics. William D. Collins of Goodwin Procter LLP acted as legal advisor; and, Morgan Stanley and Wedbush PacGrow acted as financial advisor to Disc Medicine.


© S&P Capital IQ 2022
All news about GEMINI THERAPEUTICS, INC.
09/19Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from..
CI
08/12Gemini Therapeutics Investor Alert B : Kahn Swick & Foti, LLC Investigates Merger of Gemin..
BU
08/11GEMINI THERAPEUTICS, INC. /DE Management's Discussion and Analysis of Financial Condit..
AQ
08/11Gemini Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/11Arix Bioscience To Invest $54 Million To Fund All-stock Disc Medicine, Gemini Therapeut..
MT
08/10Conference Call Transcript Gemini Th : 00 AM ET - Form 8-K
PU
08/10Gemini Therapeutics, Inc. /de : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
08/10Gemini Therapeutics Merges With Disc Medicine
MT
08/10Gemini Therapeutics : and Disc Medicine Announce Merger Agreement - Form 8-K
PU
08/10Gemini Therapeutics, Inc. /de : Entry into a Material Definitive Agreement, Regulation FD ..
AQ
More news
Analyst Recommendations on GEMINI THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -13,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,13x
Yield 2022 -
Capitalization 70,9 M 70,9 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 24
Free-Float 99,8%
Chart GEMINI THERAPEUTICS, INC.
Duration : Period :
Gemini Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GEMINI THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 1,64 $
Average target price 1,75 $
Spread / Average Target 6,71%
EPS Revisions
Managers and Directors
Georges Gemayel Executive Chairman, President & CEO
Brian Piekos Chief Financial & Business Officer
Suresh Katti Vice President-Research
Marissa Volpe Vice President-Clinical Operations
David Charles Lubner Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GEMINI THERAPEUTICS, INC.-43.64%71
MODERNA, INC.-53.44%46 259
LONZA GROUP AG-36.15%36 760
IQVIA HOLDINGS INC.-35.80%33 784
SEAGEN INC.-11.49%25 236
ALNYLAM PHARMACEUTICALS, INC.18.03%24 025